Clinical Trial Update: Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Fludarabine, Cyclophosphamide, and Rituximab followed by Zevalin in indolent non-Hodgkin lymphoma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Fludara (fludarabine)
• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: A.O. Ospedale Papa Giovanni XXIII | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: TERMINATED